We have used our unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional drug treatments. Our lead stem cell therapeutic candidate is a therapy for the treatment of patients left disabled by a stroke. Our second application for the CTX cells is for the treatment of critical limb ischaemia. Both treatments are currently in clinical development. Our hRPC stem cell candidate is for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina. Preparations for a Phase I/II clinical trial in the US have commenced and we expect the study to begin in the second half of 2015.

Most recently we have made considerable progress with our exosome platform. Exosomes are nanoparticles secreted into the culture media during the expansion of our stem cells. They contain a number of biologically active molecules such as proteins and miRNAs which have potential therapeutic benefits across a number of disease areas.

Our principal strategy is to gain clinical validation for our cell therapy programmes via well-designed clinical trials in well-regulated territories.  Ultimately, we expect to realise value for our technologies and therapeutic programmes via out-license to commercial development partners at the appropriate points in their development.  In order to achieve these objectives, we work closely with a number of key academic and industrial partners while continuing to maintain tight control over our financial resources.

ReNeuron is incorporated in and operates primarily in the UK. Our shares are traded on the London AIM market under the symbol RENE.L